Lactoferrin expression and release in neutrophils of SCN patients undergoing treatment with G-CSF. (A) Neutrophils isolated from patients 1, 2, and 3 (P1, P2, and P3) were stimulated with fMLP (10 nM), CXCL8 (10 ng/mL), or medium alone for 15 minutes. In the collected supernatants, lactoferrin concentration was determined by ELISA and expressed as average + SD of 2 distinct experiments. Statistical analysis demonstrates that the amount of lactoferrin released in supernatants derived from SCN patients is significantly lower than lactoferrin detected in supernatants from control subjects (P < .05). (B) Lactoferrin concentration in plasma of SCN patients (P1, P2, and P3) was determined in at least 3 samples. Average + SD of 3 distinct determinations is presented on y-axis. Statistical analysis demonstrates that the amount of plasma lactoferrin is lower in SCN patients compared with healthy subjects (P < .05). (C) The Western blot shown in Figures 1B and 2B has been reprobed with a specific anti–human lactoferrin antibody as described in “Patients, materials, and methods.”